{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:09:27Z","timestamp":1783465767793,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T00:00:00Z","timestamp":1538784000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biotechnol Lett"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10529-018-2612-6","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T05:44:04Z","timestamp":1538804644000},"page":"1459-1466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Anti-CD37 targeted immunotherapy of B-Cell malignancies"],"prefix":"10.1007","volume":"40","author":[{"given":"Zahra","family":"Payandeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effat","family":"Noori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahman","family":"Khalesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysam","family":"Mard-Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Abdolalizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,6]]},"reference":[{"key":"2612_CR1","doi-asserted-by":"publisher","first-page":"e496","DOI":"10.1038\/bcj.2016.106","volume":"6","author":"S Betrian","year":"2016","unstructured":"Betrian S, Ysebaert L, Heider K, Delord J, Fourni\u00e9 J, Quillet-Mary A (2016) Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant\/relapse-initiating CLL cells: a rationale for combination treatment. Blood Cancer J 6:e496","journal-title":"Blood Cancer J"},{"key":"2612_CR2","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.cbpa.2010.06.175","volume":"14","author":"J Caravella","year":"2010","unstructured":"Caravella J, Lugovskoy A (2010) Design of next-generation protein therapeutics. Curr Opin Chem Biol 14:520\u2013528","journal-title":"Curr Opin Chem Biol"},{"key":"2612_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nri1837","volume":"6","author":"PJ Carter","year":"2006","unstructured":"Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343","journal-title":"Nat Rev Immunol"},{"key":"2612_CR4","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1182\/blood-2013-05-505685","volume":"122","author":"J Deckert","year":"2013","unstructured":"Deckert J et al (2013) A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood 122:3500\u20133510","journal-title":"Blood"},{"key":"2612_CR5","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood.V126.23.1548.1548","volume":"126","author":"J Deckert","year":"2015","unstructured":"Deckert J et al (2015) IMGN529, a novel antibody-drug conjugate (ADC) targeting CD37 shows synergistic activity with rituximab in non-Hodgkin lymphoma (NHL) models. Blood 126:1548","journal-title":"Blood"},{"key":"2612_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/bcr276","volume":"3","author":"SA Eccles","year":"2001","unstructured":"Eccles SA (2001) Monoclonal antibodies targeting cancer: magic bullets or just the trigger? Breast Cancer Res 3:86","journal-title":"Breast Cancer Res"},{"key":"2612_CR7","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/eji.201242730","volume":"43","author":"KH Gartlan","year":"2013","unstructured":"Gartlan KH et al (2013) Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration. Eur J Immunol 43:1208\u20131219","journal-title":"Eur J Immunol"},{"key":"2612_CR8","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s10637-014-0125-2","volume":"32","author":"AK Gopal","year":"2014","unstructured":"Gopal AK et al (2014) Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR\u2122 therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Invest New Drugs 32:1213\u20131225","journal-title":"Invest New Drugs"},{"key":"2612_CR9","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1182\/blood-2011-04-351932","volume":"118","author":"K-H Heider","year":"2011","unstructured":"Heider K-H et al (2011) A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 118:4159\u20134168","journal-title":"Blood"},{"key":"2612_CR10","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1182\/blood.V122.21.2860.2860","volume":"122","author":"A Hellman","year":"2013","unstructured":"Hellman A et al (2013) Phase 2 study of otlertuzumab (TRU-016), an anti-CD37 ADAPTIRTM protein, in combination with bendamustine vs bendamustine alone in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 122:2860","journal-title":"Blood"},{"key":"2612_CR11","first-page":"67","volume":"1287","author":"ME Hemler","year":"1996","unstructured":"Hemler ME, Mannion BA, Barditchevski F (1996) Association of TM4SF proteins with integrins: relevance to cancer. Biochim Biophys Acta 1287:67\u201371","journal-title":"Biochim Biophys Acta"},{"key":"2612_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ccr.2012.04.034","volume":"21","author":"L Jin","year":"2012","unstructured":"Jin L, Cambier JC (2012) SMIP-016 in action: CD37 as a death receptor. Cancer Cell 21:597\u2013598","journal-title":"Cancer Cell"},{"key":"2612_CR13","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.4049\/jimmunol.172.5.2953","volume":"172","author":"K-P Knobeloch","year":"2004","unstructured":"Knobeloch K-P et al (2004) A regulatory role for CD37 in T cell. J Immunol 172:2953\u20132961","journal-title":"J Immunol"},{"key":"2612_CR14","first-page":"100","volume":"10","author":"A Kolstad","year":"2016","unstructured":"Kolstad A (2016) Efficacy and safety results of Betalutin\u00ae(177 Lu-DOTA-HH1) in a phase 1\/2 study of patients with non-hodgkin B-cell lymphoma (NHL). Platelets 10:100","journal-title":"Platelets"},{"key":"2612_CR15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/leu.2011.233","volume":"26","author":"G Krause","year":"2012","unstructured":"Krause G et al (2012) Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. Leukemia 26:546","journal-title":"Leukemia"},{"key":"2612_CR16","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","volume":"21","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella R et al (2012) Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 21:694\u2013708","journal-title":"Cancer Cell"},{"key":"2612_CR17","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrd3229","volume":"9","author":"AL Nelson","year":"2010","unstructured":"Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767","journal-title":"Nat Rev Drug Discov"},{"key":"2612_CR18","first-page":"180","volume":"22","author":"Z Payandeh","year":"2018","unstructured":"Payandeh Z, Rajabibazl M, Mortazavi Y, Rahimpour A, Taromchi AH (2018a) Ofatumumab monoclonal antibody affinity maturation through in silico modeling. Iran Biomed J 22:180","journal-title":"Iran Biomed J"},{"key":"2612_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.27457","author":"Z Payandeh","year":"2018","unstructured":"Payandeh Z, Rajabibazl M, Mortazavi Y, Rahimpour A, Taromchi AH, Dastmalchi S (2018b) Affinity maturation and characterization of the ofatumumab monoclonal antibody. J Cell Biochem. https:\/\/doi.org\/10.1002\/jcb.27457","journal-title":"J Cell Biochem"},{"key":"2612_CR20","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0067","author":"DS Pereira","year":"2015","unstructured":"Pereira DS et al (2015) AGS67E, an anti-CD37 monomethyl auristatin E antibody drug conjugate as a potential therapeutic for B\/T-cell malignancies and AML: a new role for CD37 in AML. Mol Cancer Ther. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0067","journal-title":"Mol Cancer Ther"},{"key":"2612_CR21","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1126\/science.272.5265.1173","volume":"272","author":"DR Plas","year":"1996","unstructured":"Plas DR et al (1996) Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science 272:1173\u20131176","journal-title":"Science"},{"key":"2612_CR22","first-page":"413","volume-title":"Marketed therapeutic antibodies compendium","author":"JM Reichert","year":"2012","unstructured":"Reichert JM (2012) Marketed therapeutic antibodies compendium, vol 3. Taylor & Francis, Abingdon, pp 413\u2013415"},{"key":"2612_CR23","first-page":"799","volume-title":"Antibodies to watch in 2014: mid-year update","author":"JM Reichert","year":"2014","unstructured":"Reichert JM (2014) Antibodies to watch in 2014: mid-year update, vol 4. Taylor & Francis, Abingdon, pp 799\u2013802"},{"key":"2612_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1517\/14712598.2014.890182","volume":"14","author":"T Robak","year":"2014","unstructured":"Robak T, Robak P (2014) Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opin Biol Therapy 14:651\u2013661","journal-title":"Expert Opin Biol Therapy"},{"key":"2612_CR25","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937\u20131947","journal-title":"N Engl J Med"},{"key":"2612_CR26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.4049\/jimmunol.140.3.905","volume":"140","author":"R Schwartz-Albiez","year":"1988","unstructured":"Schwartz-Albiez R, D\u00f6rken B, Hofmann W, Moldenhauer G (1988) The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol 140:905\u2013914","journal-title":"J Immunol"},{"key":"2612_CR27","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1126\/science.1241145","volume":"341","author":"MX Sliwkowski","year":"2013","unstructured":"Sliwkowski MX, Mellman I (2013) Antibody therapeutics in cancer. Science 341:1192\u20131198","journal-title":"Science"},{"key":"2612_CR28","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood.V124.21.1760.1760","volume":"124","author":"A Stathis","year":"2014","unstructured":"Stathis A et al (2014a) A phase I study of IMGN529, an antibody-drug conjugate (ADC) targeting CD37, in adult patients with relapsed or refractory b-cell non-hodgkin\u2019s lymphoma (NHL). Blood 124:1760","journal-title":"Blood"},{"issue":"15","key":"2612_CR29","doi-asserted-by":"crossref","first-page":"8526","DOI":"10.1200\/jco.2014.32.15_suppl.8526","volume":"35","author":"A Stathis","year":"2014","unstructured":"Stathis A et al (2014b) Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL). J Clin Oncol 35(15):8526","journal-title":"J Clin Oncol"},{"key":"2612_CR30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.it.2003.09.011","volume":"24","author":"JM Tarrant","year":"2003","unstructured":"Tarrant JM, Robb L, van Spriel AB, Wright MD (2003) Tetraspanins: molecular organisers of the leukocyte surface. Trends Immunol 24:610\u2013617","journal-title":"Trends Immunol"},{"key":"2612_CR31","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/0161-5890(96)84612-8","volume":"33","author":"MG Tomlinson","year":"1996","unstructured":"Tomlinson MG, Wright MD (1996) Characterisation of mouse CD37: cDNA and genomic cloning. Mol Immunol 33:867\u2013872","journal-title":"Mol Immunol"},{"key":"2612_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.imlet.2011.03.010","volume":"138","author":"S Veenbergen","year":"2011","unstructured":"Veenbergen S, van Spriel AB (2011) Tetraspanins in the immune response against cancer. Immunol Lett 138:129\u2013136","journal-title":"Immunol Lett"},{"key":"2612_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/BF00222471","volume":"37","author":"KI Virtaneva","year":"1993","unstructured":"Virtaneva KI, Angelisov\u00e1 P, Baumruker T, Ho\u0159ej\u0161\u00ed V, Nevanlinna H, Schr\u00f6der J (1993) The genes for CD37, CD53, and R2, all members of a novel gene family, are located on different chromosomes. Immunogenetics 37:461\u2013465","journal-title":"Immunogenetics"},{"key":"2612_CR34","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/nbt.3040","volume":"32","author":"G Walsh","year":"2014","unstructured":"Walsh G (2014) Biopharmaceutical benchmarks 2014. Nat Biotechnol 32:992","journal-title":"Nat Biotechnol"},{"key":"2612_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-1119(03)00400-1","volume":"306","author":"C Wu","year":"2003","unstructured":"Wu C, Sun M, Liu L, Zhou GW (2003) The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 306:1\u201312","journal-title":"Gene"},{"key":"2612_CR36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-715094","author":"ZY Xu-Monette","year":"2016","unstructured":"Xu-Monette ZY et al (2016) Assessment of CD37 B-cell antigen and cell-of-origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood. https:\/\/doi.org\/10.1182\/blood-2016-05-715094","journal-title":"Blood"},{"key":"2612_CR37","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1210\/jcem.87.2.8194","volume":"87","author":"PDO Zapata","year":"2002","unstructured":"Zapata PDO et al (2002) Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. J Clin Endocrinol Metab 87:915\u2013926","journal-title":"J Clin Endocrinol Metab"},{"key":"2612_CR38","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","volume":"110","author":"X Zhao","year":"2007","unstructured":"Zhao X et al (2007) Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110:2569\u20132577","journal-title":"Blood"}],"container-title":["Biotechnology Letters"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10529-018-2612-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10529-018-2612-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10529-018-2612-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T17:56:38Z","timestamp":1693936598000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10529-018-2612-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,6]]},"references-count":38,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2612"],"URL":"https:\/\/doi.org\/10.1007\/s10529-018-2612-6","relation":{},"ISSN":["0141-5492","1573-6776"],"issn-type":[{"value":"0141-5492","type":"print"},{"value":"1573-6776","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,6]]},"assertion":[{"value":"10 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}